Three cases of severe hepatic impairment caused by erlotinibHUANG, Yi-Sheng; AN, She-Juan; CHEN, Zhi-Hong et al.British journal of clinical pharmacology. 2009, Vol 68, Num 3, pp 464-467, issn 0306-5251, 4 p.Article

A randomized trial of systematic nodal dissection in resectable non-small cell lung cancerWU, Yi-Long; HUANG, Zhi-Fan; WANG, Si-Yu et al.Lung cancer. 2002, Vol 36, Num 1, pp 1-6, issn 0169-5002Conference Paper

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST) : a randomised phase III trial. CommentaryCULLEN, Michael; THATCHER, Nicholas; SELLERS, Mark V et al.Lancet (British edition). 2008, Vol 372, Num 9652, issn 0140-6736, 1785-1786, 1809-1818 [12 p.]Article

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trialsNING ZHAO; ZHANG, Xu-Chao; YAN, Hong-Hong et al.Lung cancer. 2014, Vol 85, Num 1, pp 66-73, issn 0169-5002, 8 p.Article

Use of Bipolar Energy for Transurethral Resection of Superficial Bladder Tumors : Long-Term ResultsPU, Xiao-Yong; WANG, Huai-Peng; WU, Yi-Long et al.Journal of endourology. 2008, Vol 22, Num 3, pp 545-549, issn 0892-7790, 5 p.Article

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN studyWU, Yi-Long; KIM, Joo-Hang; PARK, Keunchil et al.Lung cancer. 2012, Vol 77, Num 2, pp 339-345, issn 0169-5002, 7 p.Article

Comparative study of the impact of 3-versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomyPU, Xiao-Yong; WANG, Xing-Huan; WU, Yi-Long et al.Journal of cancer research and clinical oncology. 2007, Vol 133, Num 8, pp 555-562, issn 0171-5216, 8 p.Article

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)YANG, James Chih-Hsin; WU, Yi-Long; CHAN, Valorie et al.Lung cancer. 2014, Vol 83, Num 2, pp 174-181, issn 0169-5002, 8 p.Article

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung CancerSOLOMON, Benjamin J; MOK, Tony; IYER, Shrividya et al.The New England journal of medicine. 2014, Vol 371, Num 23, pp 2167-2177, issn 0028-4793, 11 p.Article

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyCIULEANU, Tudor; BRODOWICZ, Thomas; CUCEVIC, Branka et al.Lancet (British edition). 2009, Vol 374, Num 9699, pp 1432-1440, issn 0140-6736, 9 p.Article

The epidermal growth factor receptor intron 1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with GefitinibQIANG NIE; ZHEN WANG; WU, Yi-Long et al.European journal of pharmacology. 2007, Vol 570, Num 1-3, pp 175-181, issn 0014-2999, 7 p.Article

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)QING ZHOU; ZHOU, Cai-Cun; ZHANG, Xu-Chao et al.Lung cancer. 2014, Vol 83, Num 3, pp 369-373, issn 0169-5002, 5 p.Article

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitorsSONG DONG; ZHANG, Xu-Chao; HUA CHENG et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 5, pp 707-716, issn 0344-5704, 10 p.Article

KDR expression is associated with the stage and cigarette smoking of the patients with lung cancerAN, She-Juan; QIANG NIE; WU, Hong-Sui et al.Journal of cancer research and clinical oncology. 2007, Vol 133, Num 9, pp 635-642, issn 0171-5216, 8 p.Article

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung CancerSHAW, Alice T; KIM, Dong-Wan; WU, Yi-Long et al.The New England journal of medicine. 2013, Vol 368, Num 25, pp 2385-2394, issn 0028-4793, 10 p.Article

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)HOLT, Sarah V; LOGIE, Armelle; WILKINSON, Robert W et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 7, pp 1804-1813, issn 0008-5472, 10 p.Article

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non―Small-Cell Lung Cancer in Asia (IPASS)FUKUOKA, Masahiro; WU, Yi-Long; DUFFIELD, Emma L et al.Journal of clinical oncology. 2011, Vol 29, Num 21, pp 2866-2875, issn 0732-183X, 10 p.Article

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell linesHUA CHENG; AN, She-Juan; ZHANG, Xu-Chao et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 3, pp 637-646, issn 0344-5704, 10 p.Article

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung CancerQING ZHOU; ZHANG, Xu-Chao; YANG, Xue-Ning et al.Journal of clinical oncology. 2011, Vol 29, Num 24, pp 3316-3321, issn 0732-183X, 6 p.Article

Co-overexpression of Fibroblast Growth Factor 3 and Epidermal Growth Factor Receptor is correlated with the development of nonsmall cell lung carcinomaTAI, Amy L. S; SHAM, Jonathan S. T; GUAN, Xin-Yuan et al.Cancer. 2006, Vol 106, Num 1, pp 146-155, issn 0008-543X, 10 p.Article

Afatinib in the treatment of EGFR mutation-positive NSCLC ― A network meta-analysisPOPAT, Sanjay; MOK, Tony; YANG, James Chih-Hsin et al.Lung cancer. 2014, Vol 85, Num 2, pp 230-238, issn 0169-5002, 9 p.Article

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors PhosphorylationYANG, Jin-Ji; ZHANG, Xu-Chao; ZHEN WANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 5, pp 1383-1392, issn 1078-0432, 10 p.Article

Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST studyHEIGENER, David F; WU, Yi-Long; VAN ZANDWIJK, Nico et al.Lung cancer. 2011, Vol 74, Num 2, pp 274-279, issn 0169-5002, 6 p.Article

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urinePU, Xiao-Yong; WANG, Zhi-Ping; CHEN, Yi-Rong et al.Journal of cancer research and clinical oncology. 2008, Vol 134, Num 6, pp 659-665, issn 0171-5216, 7 p.Article

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patientsRONG LI; AN, She-Juan; CHEN, Zhi-Hong et al.Human pathology. 2008, Vol 39, Num 12, pp 1792-1801, issn 0046-8177, 10 p.Article